Electroacupuncture for older adults with mild cognitive impairment: study protocol for a randomized controlled trial by unknown
TRIALS
Leung et al. Trials  (2015) 16:232 
DOI 10.1186/s13063-015-0740-zSTUDY PROTOCOL Open AccessElectroacupuncture for older adults with mild
cognitive impairment: study protocol for a
randomized controlled trial
Albert Wing Nang Leung1*, Linda Chiu Wa Lam2, Andrew Ka Lun Kwan1, Celia Lai Lin Tsang1, Hong Wei Zhang1,
Yuan Qi Guo1 and Chuan Shan Xu1,3*Abstract
Background: Mild cognitive impairment is an intermediary state between normal aging and clinical Alzheimer’s
disease. Early intervention of mild cognitive impairment may be an important strategy in the management of
Alzheimer’s disease. The proposal aims to evaluate if electroacupuncture would optimize cognitive function in
subjects with mild cognitive impairment and understand the role of electroacupuncture in the treatment of
Alzheimer’s disease.
Methods/design: A randomised patient- and assessor-blind sham-controlled trial is designed to assess whether
electroacupuncture intervention decreases the rate of cognitive decline amongst older adults with mild cognitive
impairment. One hundred and fifty subjects aged 65 years of age or over with a diagnosis of mild cognitive
impairment are recruited from the community and elderly centre in Hong Kong. All subjects are randomly
allocated into two groups (75 subjects each group): the electroacupuncture group and sham control. Participants
in the electroacupuncture group receive electroacupuncture stimulation by sterile, disposable acupuncture
needles inserted to the acupoints with a depth of 1 to 3 cm. The acupuncture needles are subjected to 2 Hz
electroacupuncture wihtat an intensity of 5 to 10 mA. Each participant receives electroacupuncture for 8 weeks
(once a day, 3 days a week) and the treatment lasts for 30 minutes each time. For sham electroacupuncture,
needles are inserted to a depth of 1 to 2 mm, and connected to the electroacupuncture device without any
current passing through. Outcome measures (including primary and secondary outcome measures) are collected
at baseline, at the end day of intervention, and months 4 and 6 after intervention. The primary outcome is
measured by the Alzheimer Disease Assessment Scale-Cognitive subscale. Secondary outcomes are measured by
the mini-mental state examination, category fluency text and the Short Form 12.
Discussion: The study will provide evidence for evaluating and understanding the role of electroacupuncture in
the treatment of Alzheimer’s disease.
Trial registration: This trial is registered with chictr.org (registration number: ChiCTR-TRC-12002414. Registration
date: 11 August 2012.
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Fig. 1 Study flow chart
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Nowadays, nearly 25 million people have been diagnosed
with dementia worldwide, and the number is increasing by
5 million each year [1]. Alzheimer’s disease (AD) is a com-
mon dementia in older people. Patients with AD usually
suffer from a progressive decline in their cognition and
functional ability [2, 3]. These mental disorders seriously
affect the quality of daily life of patients with AD. As the
Hong Kong population has aged rapidly in recent years,
AD has become an important public health problem in
Hong Kong [4, 5].
The current strategy mainly relies on complementary
medicine for improving quality of life and delaying cogni-
tive decline of patients with AD. However, there is as yet
no really satisfactory treatment. It is well known that AD
is a progressively cognitive decline, and mild cognitive im-
pairment (MCI) is an intermediary state between normal
aging and clinical AD [6, 7]. The older adults with MCI
are at increased risk for conversion to clinical AD [2, 6, 7].
Emerging evidence shows that early improvement of MCI
is very beneficial to decrease the prevalence of AD [8].
Thus, there is an urgent need to search novel and effective
approaches for treating MCI.
Acupuncture is a common technique for treating neur-
opathy in traditional Chinese medicine. Manual and elec-
trical stimulation on the acupoints are commonly used
stimulation modes of acupuncture [9]. Increasing evidence
shows that electroacupuncture could reduce the functional
deficits of neurophathy [10] and prevent cognitive defi-
ciency involved in brain diseases [11]. Jing and colleagues
[12] showed that electroacupuncture could significantly im-
prove learning and memory capacity. In mainland China,
acupuncture has been used as an alternative medicine for
AD and is claimed to be effective in improving intelligence.
Recently, Xue and colleagues [13, 14] reported that electro-
acupuncture may effectively improve the learning-memory
capacity of amyloid precursor protein transgenic AD mice
and alleviate the pathological changes in neurons of the
hippocampal region. Zhao and colleagues [15] showed that
electroacupunture could shorten the waiting time for rec-
ognition and decrease the psychological stress. Many rele-
vant clinical studies of electroacupuncture for dementia
have been carried out in mainland China and benefit was
reported in up to 70 to 90 % of the treatment group, but a
review from the Cochrane Collaboration demonstrated that
true randomised controlled trials and high-quality trials are
non-existent [16, 17]. Randomised controlled trials are ur-
gently needed.
Objective
The primary objective of this study is to evaluate if electroa-
cupuncture can optimize cognitive function in subjects
with MCI, and to understand the role of electroacupunc-
ture in the treatment of AD.Methods/design
Study design
The study is a randomised, patient- and assessor-blind
sham-controlled trial with a 1:1 allocation ratio. The sub-
jects (n = 150) are randomly allocated to the electroacu-
puncture group (n = 75) and sham control group (n = 75).
This project is approved by the Joint Chinese University of
Hong Kong-New Territories East Cluster Clinical Research
Ethics Committee (CRE-2011.515-T). Written informed
consent is obtained from each participant. The design is de-
scribed in Fig. 1.Participants
Subjects who aged 65 years of age or over with a diagnosis
of MCI are recruited from the community and elderly
centre in Hong Kong.Inclusion criteria
All subjects are assessed using the Clinical Dementia Rat-
ing. Case definition of MCI is based on Peterson’s criteria.
In this project, the eligible criteria are adopted following
the methods described by Lam and colleagues [5, 18]. The
participants should be willing and able to travel to our
treatment sites.
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The exclusion criteria are as follows: dementia, AD, notable
cognitive impairment (score of 23 or less as evidenced by
mini-mental state examination (MMSE), current psychiatric
disorders (for example, depression, anxiety), history of alco-
hol or drug abuse, bleeding disorder, currently undergoing
acupuncture/taking drug for cognitive problems, or cur-
rently treated with medications affecting cognition or other
serious illnesses (for example, clinically significant active
heart, renal, or hepatic diseases). Patients who have diffi-
culty in reading and understanding study questionnaire are
also excluded.
Interventions
Participants randomised to the electroacupuncture group
will receive electroacupuncture stimulation after baseline
assessment. The electroacupuncture treatment is carried
out by a Chinese Medicine Practitioner registered with the
Chinese Medicine Council of Hong Kong, who has at least
3 years of clinical acupuncture experience. From the view
of Chinese medicine theory, the deficiency of the kidney is
the main pathogenesis of MCI; thus, each participant will
receive electroacupuncture at traditional acupuncture
points: EX-HN1 (Sishencong); GV20 (Baihui); GB13 (Ben-
shen); GB20 (Fengchi); GB39 (Xuanzhong); DU24 (Shent-
ing); KI3 (Taixi) [19, 20]. The rationale for choosing the
acupoints is as follows: the acupoints on the head such as
EX-HN1 (Sishencong), GV20 (Baihui), GB13 (Benshen),
DU24 (Shenting), and GB20 (Fengchi) have the local effect
of regulating the brain function; the other acupoints on
the lower limb, such as GB39 (Xuanzhong), and KI3
(Taixi), have the effect of tonifying the kidney [19, 20].
Sterile, disposable acupuncture needles with a diameter of
0.20 mm are used in the study. The puncture is made in
accordance with the standards of traditional Chinese
medicine, to a depth of 1 to 3 cm depending on the thick-
ness of the local tissues. The acupoints are subjected to 2
Hz electroacupuncture from an electroacupuncture device
(Hwato, Electronic Acupuncture Treatment Instrument,
Suzhou Medical Appliance Factory, Jiangsu, China) at an
intensity (5 to 10 mA) that can produce a muscle twitch
acceptable to the participant. Each participant in the elec-
troacupuncture group receives electroacupuncture for 8
weeks (once a day, 3 days a week) and the treatment lasts
for 30 minutes each time [19, 20].
Participants randomised to the sham control group re-
ceive sham electroacupuncture treatment. For sham elec-
troacupuncture, the short acupuncture needle is inserted
to a depth of 1 to 2 mm, which is deep enough to make
the acupuncture needle stand up on the skin. The needles
are only connected to the electroacupuncture device with-
out any current passing through [21, 22]. Other treatment
procedures are similar to those of the electroacupuncture
group.All participants are advised not to seek any other alter-
native treatment affecting cognitive function (including
any traditional Chinese medicine treatment or laser acu-
puncture, or moxibustion or other physiotherapies) during
the trial period. Treatment compliance is also monitored
at each appointment.
Randomisation
Participants are randomly allocated to either the electroacu-
puncture group or sham control group after the baseline
assessment. The randomisation is performed according to
computer generated random allocation treatment codes.
The randomisation list is kept by an independent investiga-
tor not involving in the care or assessment of the partici-
pants, or in the data collection and analysis.
Blinding
All participants receive similar treatment procedures. All
investigators who administer the outcome measurement
questionnaire and statistician are blinded to the random-
isation status. In order to blind the patients, we also tell
them that the electric stimulation is rather mild and
some may have no obvious sensation during treatment.
Primary outcome
Cognitive decline is measured using the Chinese version
of the Alzheimer Disease Assessment Scale-Cognitive sub-
scale (ADAS-cog) [13]. The ADAS-cog is sensitive to
change over time, including some subscales for testing list
learning, object naming, commands, ideational apraxia,
construction, orientation, and recognition. The total pos-
sible score is 70. A score increase indicates greater severity
of impairment.
The ADAS-cog is assessed at baseline (before interven-
tion), at 8 weeks (the end of intervention) and months 4
and 6 after intervention.
Secondary outcome
Secondary measures include the MMSE, category fluency
test (CFT) and the Short Form 12 (SF12) [2, 18, 23].
The MMSE is an 11-question measure that tests five
areas of cognitive function (orientation, registration, at-
tention and calculation, recall, and language). The max-
imum score is 30 and a score below 24 is considered
abnormal for dementia screening [2].
The CFT is used for evaluating patient executive function,
semantic memory and language. The CFT requires the sub-
jects to generate exemplars in three categories for 1 minute
per category as described by Lam and colleagues [18].
The SF12 includes 12 items testing eight concepts of
both physical and mental health. The physical and mental
component summary scales are scored using norm-based
methods [23].
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fore intervention), at 8 weeks (the end of intervention)
and months 4 and 6 after intervention.
Other outcomes
Adverse events are assessed by a Chinese Medicine Practi-
tioner at each session of acupuncture. If the participants
feel discomfort, such as vomiting, nausea, dizziness, or dry
mouth or itching after acupuncture, these events are re-
corded and assessed at the end of treatment [24]. Add-
itionally, the use of other any additional treatment or
drugs must be recorded during follow-up.
Sample size
Base on previous related studies [25–27], we assume the
standard deviation of ADAS-cog to be 6. To detect a 3-
point change on the scale of ADAS-cog between the elec-
troacupuncture and sham treatment groups, a sample size
of 126 will be needed with a false-positive error of 5 % and
power of 80 %. Since an overall dropout rate of 20 % was
anticipated, the required sample size will be 150 (75 pa-
tients per group).
Data analysis
The differences between electroacupuncture and sham
treatment group are assessed by an analysis of covariance
using baseline score as a covariate for the primary vari-
ables. Descriptive statistics and an analysis of covariance
in the presence of baseline covariates are conducted for
the secondary variables. A generalized linear model is used
to adjust for possible confounding variables such as age,
sex, social class, and so forth. Categorical data are ana-
lysed by means of chi-squared tests. A non-parametric ap-
proach (Mann-Whitney test) is used to analyse the
subscales and interval data. Frequency tables and charts
are used to analyse questions in the adverse events ques-
tionnaire. All statistical analyses are performed using the
Statistical Package for Social Sciences (SPSS, SPSS Inc.,
Chicago, USA) version 16.0. A two-sided P-value of 0.05
or less is considered to be significant.
Discussion
Current management of AD mainly takes a comprehensive
approach, including pharmacological and non-pharmaco-
logical interventions for cognitive and neuropsychiatric
symptoms. MCI is considered an at-risk state for further
cognitive deterioration. At present, there is no drug ap-
proved for the prevention of cognitive decline in people with
MCI. The present study is designed to evaluate if electroacu-
puncture can optimize cognitive function in subjects with
MCI and to understand the role of electroacupuncture in
the treatment of Alzheimer’s disease.
A successful blinding during the trial will help maintain
the comparability between groups. All investigators whoadminister the outcome measurement questionnaire and
statistician are blinded to the randomisation status. We will
also take measures to blind the patients. A conventional
treatment is given to patients in both groups. Although we
could not blind the acupuncturists, detailed instruction,
such as how to avoid unnecessary conversation, to minim-
ise the possible patient-practitioner interaction is given to
them. When the acupuncturists withdraw the sham needle,
they are also instructed to block the patients’ line of sight
with their back or hand. The advice given to patients not to
seek other treatment aims also to help maintain the com-
parability between groups.
Allocation concealment methods seem to adequately
guard against bias. In the trial, a colleague who is not in-
volved in the baseline assessment is responsible for prepar-
ing the sequentially numbered, opaque, sealed envelopes
that contain the intervention group assignment based on
the random list generated by the computer program. After
the eligible patients enter the trial, the acupuncturist will
open the envelopes to find the intervention assignment.
In the acupuncture clinic, most acupuncturists individu-
alise their interventions based on the constitutional and
traditional Chinese medicine diagnosis of the individual
presenting with symptoms. Considering that a formulaic,
fixed acupuncture protocol is relatively easy to generalize
to different regions worldwide and to decrease study bias,
we chose uniform acupoints for all the participants in the
trial. Additionally, the sham control intervention we used
in the trial is really called minimal acupuncture or superfi-
cial needling, which has been often used as a sham control
in clinical acupuncture trials in the last 20 years [21]. For
the study of the efficacy of electroacupucnture, a sham
acupuncture in the form of superficial needling may con-
trol for needle penetration [22]. Although a possible effect
of superficial needling may exist, it is assumed to be rather
small with a needling depth of 1 to 2 mm and without
electrical stimulation compared to the normal acupunc-
ture with a needling depth of 10 to 30 mm and electrical
stimulation. It should be a better choice than non-
penetration needling as a control as we want to achieve a
better blinding effect in the efficacy study.
At the end of this project, the preventative potential will
be discussed in light of the results obtained. The findings
of the project are expected to provide evidence for the ef-
ficacy of electroacupuncture treatment in improving cog-
nitive function in people with MCI.Trial status
This trial is currently ongoing.
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